Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 7/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.36 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.36 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21065635 | 0.88 | DRD2 (0.37) | PNMTADRA2AADRA2BADRA2CDRD2 | |
| SCHEMBL21942491 | 0.82 | PNMT (0.37) | PNMTADRA2AADRA2BADRA2CDRD2 | |
| SCHEMBL23329956 | 0.82 | PNMT (0.35) | PNMTADRA2AADRA2BADRA2C | |
| SCHEMBL20889646 | 0.82 | CD44 (0.34) | PNMT | |
| SCHEMBL20883894 | 0.81 | HRH3 (0.38) | — | |
| SCHEMBL25085614 | 0.81 | PNMT (0.35) | PNMTADRA2AADRA2BADRA2C | |
| SCHEMBL7921103 | 0.78 | PNMT (0.55) | PNMTADRA2AADRA2BADRA2CDRD2 | |
| SCHEMBL21659168 | 0.76 | ASIC3 (0.35) | PNMTDRD2DRD3 | |
| SCHEMBL25085608 | 0.75 | — | — | |
| SCHEMBL25085621 | 0.75 | PPARD (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11179473-B2 | Nectin-4 antibody conjugates and uses thereof | SILVERBACK THERAPEUTICS, INC. (US) | 2021-11-23 | — | — | US | disclosed |
| US-20210275683-A1 | NECTIN-4 ANTIBODY CONJUGATES AND USES THEREOF | ARARIS BIOTECH AG (CH) | 2021-09-09 | — | — | US | disclosed |
| US-10428045-B2 | Benzazepine compounds, conjugates, and uses thereof | SILVERBACK THERAPEUTICS, INC. (US) | 2019-10-01 | — | — | US | disclosed |
| US-20190169165-A1 | BENZAZEPINE COMPOUNDS, CONJUGATES, AND USES THEREOF | SILVERBACK THERAPEUTICS, INC. | 2019-06-06 | — | — | US | disclosed |
| US-20190169164-A1 | BENZAZEPINE COMPOUNDS, CONJUGATES, AND USES THEREOF | SILVERBACK THERAPEUTICS, INC. | 2019-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210275683-A1 | NECTIN-4 ANTIBODY CONJUGATES AND USES THEREOF | NECTIN4, SIGLEC7, CD2 | PNMT 2977/4885ADRA2A 2783/4885ADRA2B 2482/4885 |
| US-20190169164-A1 | BENZAZEPINE COMPOUNDS, CONJUGATES, AND USES THEREOF | TLR8, TLR3, TLR5 | PNMT 596/4885ADRA2A 796/4885ADRA2B 880/4885 |
| US-11179473-B2 | Nectin-4 antibody conjugates and uses thereof | NECTIN4, SIGLEC7, CD2 | PNMT 2977/4885ADRA2A 2783/4885ADRA2B 2482/4885 |
| US-10428045-B2 | Benzazepine compounds, conjugates, and uses thereof | TLR8, TLR3, TLR5 | PNMT 596/4885ADRA2A 796/4885ADRA2B 880/4885 |
| US-20190169165-A1 | BENZAZEPINE COMPOUNDS, CONJUGATES, AND USES THEREOF | TLR8, TLR3, TLR5 | PNMT 596/4885ADRA2A 796/4885ADRA2B 880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.